{
    "brief_title": "Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer",
    "phase": "Phase 2",
    "drugs": "['Apatinib', 'capecitabine']",
    "drugs_list": [
        "Apatinib",
        "capecitabine"
    ],
    "diseases": "['Triple-negative Breast Cancer']",
    "diseases_list": [
        "Triple-negative Breast Cancer"
    ],
    "enrollment": "80.0",
    "inclusion_criteria": "inclusion criteria: \n\n Age\uff1a18 \n\n 75 years; \n\n Triple-negative breast cancer (TNBC) confirmed by histology examination; \n\n patients had received first-line combination chemotherapy for advanced metastatic disease, and had a complete response, partial response or stable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; \n\n received endocrine therapy for metastatic disease before first-line chemotherapy were allowed; \n\n Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; \n\n A life expectancy of more than 12 weeks; \n\n Baseline blood routine examination in accordance with the following criteria : ANC\u22651.5\u00d7109/L\uff0cPLT\u226590\u00d7109/L\uff0cHb\u226590g/L; \n\n Liver and renal function in accordance with the following criteria: total bilirubin less than 1.5 times the upper limit of normal value; aspartate aminotransferase (AST), or alanine aminotransferase (ALT) less than 2.5 times the upper limit of normal value, less than 5 times the upper limit of normal value in patients with liver metastases. \n\n the creatinine clearance rate calculated greater than 60 mL/min; \n\n Females of childbearing potential must be a pregnancy test in 7 days before participating ( including serum or urine), and the results were negative, and they are willing to take effective contraceptive methods During the trial and within 8 weeks after the last dose; \n\n Obtain informed consent from patients before starting any research-related operations and treatments to confirm that patients are willing to participate in this study and comply with research-related requirements. \n\n ",
    "exclusion_criteria": ": \n\n Metastasis/recurrence occurs within 6 months of adjuvant chemotherapy; \n\n controlled high blood pressure, systolic blood pressure \u2265150mmHg or diastolic blood pressure \u2265100mmHg; \n\n urine routine test with urinary protein more than ++, or 24 hour urinary protein more than 1.0 g; \n\n abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN+4 seconds or APTT >1.5 times the ULN); \n\n Pregnant or lactating woman; \n\n Symptomatic brain parenchymal and/or pia mater metastases without treatment and control; \n\n Patients with Other malignant tumors in the past 5 years, except for fully treated cervical carcinoma in situ, cutaneous squamous cell carcinoma or well-controlled localized basal cell skin cancer; \n\n Mental illness or other condition that affects patient compliance; \n\n serious and uncontrollable systemic diseases (eg clinically significant cardiovascular disease, lung or metabolic disease, arteriovenous thrombosis, etc.) happened recently; \n\n Can not take or absorb oral drugs; \n\n Receiving any other testing drugs, or participating in other clinical trial 30 days before being enrolled in this trial; \n\n The patient has previously received treatment with an anti-angiogenic drug (whether adjuvant or palliative); \n\n Known or suspected to be allergic to any research drug or excipient; \n\n Any other researcher believes that it is not appropriate to participate in this test.",
    "brief_summary": "The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer",
    "NCT_ID": "NCT03775928"
}